Verapamil
Verapamil, Verelan (verapamil) is a small molecule pharmaceutical. Verapamil was first approved as Isoptin on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1C and voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 10, sodium leak channel NALCN, voltage-dependent L-type calcium channel subunit alpha-1D, potassium voltage-gated channel subfamily C member 2, cytochrome P450 3A4, voltage-dependent L-type calcium channel subunit alpha-1F, two pore channel protein 1, two pore channel protein 2, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Verelan (generic drugs available since 1986-10-01, discontinued: Calan, Covera, Isoptin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trandolapril
+
Verapamil hydrochloride
Verapamil hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VERAPAMIL HYDROCHLORIDE | Exela Pharma Sciences | N-018925 RX | 1984-03-30 | 1 products |
| VERELAN | Societal CDMO | N-019614 RX | 1990-05-29 | 4 products, RLD |
| VERELAN PM | Societal CDMO | N-020943 RX | 1998-11-25 | 3 products, RLD, RS |
Show 7 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| calananz | OTC monograph final | 2023-05-18 |
| verapamil hci | ANDA | 2024-02-01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08D: Selective calcium channel blockers with direct cardiac effects
— C08DA: Phenylalkylamine derivatives, selective calcium channel blockers with direct cardiac effects
— C08DA01: Verapamil
— C08DA51: Verapamil, combinations
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB10: Trandolapril and verapamil
HCPCS
No data
Clinical
Clinical Trials
176 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | 7 | 5 | 14 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | 3 | 3 | 5 | 13 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | 2 | 2 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 1 | 1 | 4 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | 1 | 1 | 3 |
| Percutaneous coronary intervention | D062645 | — | — | — | — | — | 2 | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | 1 | 1 | — | 3 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | 2 | 1 | 1 | — | 3 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | 1 | 2 |
| Microvascular angina | D017566 | — | — | — | — | — | 1 | 1 | 2 |
Show 22 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Phenylketonurias | D010661 | — | E70.0 | — | 1 | 6 | — | 2 | 9 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | 2 | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 1 | — | — | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | 1 | 2 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 1 | — | — | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 1 | 2 |
| Essential hypertension | D000075222 | — | I10 | — | — | 1 | — | 1 | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | 1 | — | — | 1 |
| Mania | D000087122 | — | F30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 18 | 1 | — | — | 1 | 19 |
| Pharmacokinetics | D010599 | — | — | 2 | 1 | — | — | — | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | 1 | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | 1 | 2 |
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | 1 | 1 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | 1 | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 1 | — | — | — | 1 |
| Myoclonic epilepsies | D004831 | HP_0002123 | G40.4 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | 4 | — | — | — | — | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | 1 | — | — | — | 1 | 2 |
| Nasal polyps | D009298 | HP_0100582 | J33 | 1 | — | — | — | 1 | 2 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 1 | — | — | — | — | 1 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | — | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| No-reflow phenomenon | D054318 | — | — | — | — | — | — | 2 | 2 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 2 | 2 |
| Coronary angiography | D017023 | — | — | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | — | 1 | 1 |
| Hemangioendothelioma | D006390 | — | — | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 1 | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Verapamil |
| INN | verapamil |
| Description | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile is a tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a tertiary amino compound, an aromatic ether, a polyether and a nitrile. |
| Classification | Small molecule |
| Drug class | coronary vasodilators (verapamil type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 52-53-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL6966 |
| ChEBI ID | 77733 |
| PubChem CID | 2520 |
| DrugBank | DB00661 |
| UNII ID | CJ0O37KU29 (ChemIDplus, GSRS) |
Target
Agency Approved
CACNA1C
CACNA1C
CACNA1S
CACNA1S
Organism
Homo sapiens
Gene name
CACNA1C
Gene synonyms
CACH2, CACN2, CACNL1A1, CCHL1A1
NCBI Gene ID
Protein name
voltage-dependent L-type calcium channel subunit alpha-1C
Protein synonyms
CACNA1C intronic transcript 2, CACNA1C intronic transcript 2 (non-protein coding), calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit, Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle, calcium channel, voltage-dependent, L type, alpha 1C subunit, DHPR, alpha-1 subunit, voltage-dependent L-type Ca2+ channel alpha 1 subunit, Voltage-gated calcium channel subunit alpha Cav1.2
Uniprot ID
Mouse ortholog
Cacna1c (12288)
voltage-dependent L-type calcium channel subunit alpha-1C (Q99242)
Alternate
SLC29A4
SLC29A4
KCNA7
KCNA7
KCNA10
KCNA10
NALCN
NALCN
CACNA1D
CACNA1D
KCNC2
KCNC2
CYP3A4
CYP3A4
CACNA1F
CACNA1F
TPCN1
TPCN1
TPCN2
TPCN2
KCNJ6
KCNJ6
Organism
Homo sapiens
Gene name
SLC29A4
Gene synonyms
ENT4, PMAT
NCBI Gene ID
Protein name
equilibrative nucleoside transporter 4
Protein synonyms
Plasma membrane monoamine transporter, PMAT, solute carrier family 29 (equilibrative nucleoside transporter), member 4, solute carrier family 29 (nucleoside transporters), member 4, Solute carrier family 29 member 4
Uniprot ID
Mouse ortholog
Slc29a4 (243328)
equilibrative nucleoside transporter 4 (Q8R139)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Verelan – Elan Corporation
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Verapamil
+
Trandolapril
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Verapamil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 32,294 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,930 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use